David H Aggen, MD PhD· @Dr_Aggen · X·· 23 小时前评分70
正文 · 原文
VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert
EFS HR 0.51
OS HR 0.58
pCR rate 44%
224 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：David H Aggen, MD PhD · x.com